USPTO serial 79377825
Y VECTORY THERAPEUTICS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 7, 2025
- Examiner
- THOMPSON, HEATHER
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with Y VECTORY THERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Douglas T. Johnson
Douglas T. Johnson Miller & Martin PLLC832 Georgia AvenueSuite 1200Chattanooga, TN 37402Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Viral systems, gene therapy systems, nucleic acid delivery systems, namely, viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, gene therapy vectors or nucleic acid delivery vectors for medical purposes; pharmaceutical products for the treatment of neurodegenerative disease; biological preparations for use in medical and clinical gene therapy, nucleic acid-based therapy; clinical medical reagents for use in gene therapy; pharmaceutical preparations, vaccines, prophylaxis products and other pharmaceutical products for use in gene therapy | ACTIVE | — |
| 042 | Research, product development and consultancy in the field of biotechnology, biologics and medical science; research and product development in the field of pharmaceutics | ACTIVE | — |
| 044 | Gene and nucleic acid delivery by viral vectors, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders; consultancy in the field of pharmaceutics | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by VectorY B.V.
- Other trademarks owned by VectorY B.V.
- Other trademarks owned by VectorY B.V.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named Y VECTORY THERAPEUTICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 26, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 5, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 5, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 7, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Feb 15, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jan 27, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 26, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jan 7, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 7, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 19, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 19, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 13, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 7, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 27, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 27, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 27, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 24, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 29, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 28, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 10, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 9, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 6, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 12, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 7, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 31, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |